BIO-key International, Inc. (NASDAQ:BKYI) Short Interest Down 26.6% in June

BIO-key International, Inc. (NASDAQ:BKYI) saw a large decline in short interest during the month of June. As of June 30th, there was short interest totalling 27,800 shares, a decline of 26.6% from the May 30th total of 37,900 shares. Approximately 0.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 11,400 shares, the short-interest ratio is presently 2.4 days.

BKYI remained flat at $$1.24 during trading on Thursday. 5,900 shares of the company’s stock were exchanged, compared to its average volume of 20,155. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.15 and a quick ratio of 1.56. The business’s 50-day simple moving average is $1.16. BIO-key International has a twelve month low of $0.75 and a twelve month high of $2.70.

BIO-key International (NASDAQ:BKYI) last released its earnings results on Wednesday, May 15th. The technology company reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.09). BIO-key International had a negative return on equity of 60.41% and a negative net margin of 172.60%. The business had revenue of $0.55 million during the quarter.

Separately, Maxim Group set a $8.00 target price on shares of TrovaGene and gave the stock a “buy” rating in a research note on Tuesday, April 2nd.

About BIO-key International

BIO-key International, Inc develops and markets fingerprint biometric identification and identity verification technologies, authentication-transaction security technologies, and related identity management and credentialing biometric hardware and software solutions. Its solutions enable application developers, value added resellers, and channel partners to integrate fingerprint biometrics into their applications.

Featured Article: Percentage Gainers

Receive News & Ratings for BIO-key International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-key International and related companies with's FREE daily email newsletter.